Bemcentinib – A selective AXL inhibitor currently in Phase II
Learn MoreINVESTORS
Go to stock watchScientific Presentations
CROI 2021, Wendy Maury et al.
6 March 2021
Targeting of the Receptor Tyrosine Kinase AXL by Bemcentinib prevents SARS-CoV-2 infection
Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.
BerGenBio’s lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Additionally, bemcentinib has been reported to exhibit potent anti-viral activity in preclinical models of infection by enveloped viruses, including Ebola and Zika. Recent data have expanded this to SARS-CoV-2 where findings suggest that bemcentinib stops the virus entering the host cells and neutralising its anti-viral defence mechanisms. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BERGENBIO ASA: Minutes from the Annual General Meeting
Bergen, Norway, 19 March 2021 – Annual General Meeting in BerGenBio ASA (OSE:BGBIO) was virtually held on 19 March 2021 at 15.00 hours CET. All proposals were resolved as presented in
Read moreBERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Bergen, Norway, 6 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on
Read moreBERGENBIO CLOSES RECRUITMENT INTO TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 4th March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has closed recruitment
Read moreBERGENBIO ASA: ANNUAL REPORT 2020
Bergen, Norway, 25 February 2021 – Reference is made to the notice on 23 February 2021 and the Board of Directors approval of BerGenBio ASA’s (OSE:BGBIO) Annual Financial statement. The Annual Report for
Read more
